In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [ 11C]methylphenidate and PET

NeuroImage

Volumn 59, Issue 3, 2012, Pages 2413-2422

  Fischer, Kristina ^a   Sossi, Vesna ^b   Von Ameln Mayerhofer, Andreas ^a   Reischl, Gerald ^a   Pichler, Bernd J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

11C methylphenidate; Dopamine transporter; Mice; Partial volume effect; PET

Indexed keywords

DOPAMINE TRANSPORTER; METHYLPHENIDATE C 11; OXIDOPAMINE; TRACER; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING KINETICS; BOLUS INJECTION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG INFUSION; EX VIVO STUDY; IN VIVO STUDY; MALE; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; RADIOACTIVITY; REPRODUCIBILITY; TEST RETEST RELIABILITY;

ALGORITHMS; ANIMALS; AUTORADIOGRAPHY; CEREBELLUM; CORPUS STRIATUM; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNCTIONAL LATERALITY; IMAGE PROCESSING, COMPUTER-ASSISTED; KINETICS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPHENIDATE; MICE; MICE, INBRED C57BL; OXIDOPAMINE; POSITRON-EMISSION TOMOGRAPHY; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SOFTWARE;

EID: 84855456432     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.08.109     Document Type: Article

References (52)

1. Abramoff M.D., Magelhaes P.J., Ram S.J. Image Processing with ImageJ. Biophotonics Int. 2004, 11:36-42.
2. Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T., Uitti R.J., Calne D.B., Wszolek Z.K., Stoessl A.J. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128:2777-2785.
3. Alvarez-Fischer D., Blessmann G., Trosowski C., Behe M., Schurrat T., Hartmann A., Behr T.M., Oertel W.H., Hoglinger G.U., Hoffken H. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease. NeuroImage 2007, 38:5-12.
4. Byas-Smith M.G., Li J., Szlam F., Eaton D.C., Votaw J.R., Denson D.D. Isoflurane induces dopamine transporter trafficking into the cell cytoplasm. Synapse 2004, 53:68-73.
5. Carson R.E., Channing M.A., Blasberg R.G., Dunn B.B., Cohen R.M., Rice K.C., Herscovitch P. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J. Cereb. Blood Flow Metab. 1993, 13:24-42.
6. Casteels C., Lauwers E., Bormans G., Baekelandt V., Van Laere K. Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:124-134.
7. Casteels C., Lauwers E., Baitar A., Bormans G., Baekelandt V., Van Laere K. In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease. Brain Res. 2010, 1316:153-162.
8. Constantinescu C.C., Mukherjee J. Performance evaluation of an Inveon PET preclinical scanner. Phys. Med. Biol. 2009, 54:2885-2899.
9. Davie C.A. A review of Parkinson's disease. Br. Med. Bull. 2008, 86:109-127.
10. Ding Y.S., Fowler J.S., Volkow N.D., Gatley S.J., Logan J., Dewey S.L., Alexoff D., Fazzini E., Wolf A.P. Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. Synapse 1994, 18:152-160.
11. Ding Y.S., Sugano Y., Fowler J.S., C., S. Synthesis of the racemate and individual enantiomeres of [11C]methylphenidate for studying presynaptic dopaminergic neuron with positron emission tomography. J. Labelled Compd. Radiopharm. 1994, 34.
12. Ding Y.S., Fowler J.S., Volkow N.D., Logan J., Gatley S.J., Sugano Y. Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain. J. Nucl. Med. 1995, 36:2298-2305.
13. Doudet D.J., Rosa-Neto P., Munk O.L., Ruth T.J., Jivan S., Cumming P. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study. NeuroImage 2006, 30:26-35.
14. Eriksen J., Jorgensen T.N., Gether U. Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J. Neurochem. 2010, 113:27-41.
15. Fischer K., Sossi V., Schmid A., Thunemann M., Maier F.C., Judenhofer M.S., Mannheim J.G., Reischl G., Pichler B.J. Noninvasive nuclear imaging enables the in vivo quantification of striatal dopamine receptor expression and raclopride affinity in mice. J. Nucl. Med. 2011, 52:1133-1141.
16. Gatley S.J., Ding Y.S., Volkow N.D., Chen R., Sugano Y., Fowler J.S. Binding of d-threo-[11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine. Eur. J. Pharmacol. 1995, 281:141-149.
17. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612.
18. Harada N., Ohba H., Fukumoto D., Kakiuchi T., Tsukada H. Potential of [(18)F]beta-CFT-FE (2beta-carbomethoxy-3beta-(4-fluorophenyl)-8-(2-[(18)F]fluoroethyl)nortropane) as a dopamine transporter ligand: A PET study in the conscious monkey brain. Synapse 2004, 54:37-45.
19. Henze C., Earl C., Sautter J., Schmidt N., Themann C., Hartmann A., Oertel W.H. Reactive oxidative and nitrogen species in the nigrostriatal system following striatal 6-hydroxydopamine lesion in rats. Brain Res. 2005, 1052:97-104.
20. Hoffman E.J., Huang S.C., Phelps M.E. Quantitation in positron emission computed tomography: 1. Effect of object size. J. Comput. Assist. Tomogr. 1979, 3:299-308.
21. Honer M., Hengerer B., Blagoev M., Hintermann S., Waldmeier P., Schubiger P.A., Ametamey S.M. Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice. Nucl. Med. Biol. 2006, 33:607-614.
22. Hume S.P., Myers R., Bloomfield P.M., Opacka-Juffry J., Cremer J.E., Ahier R.G., Luthra S.K., Brooks D.J., Lammertsma A.A. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse 1992, 12:47-54.
23. Hume S.P., Gunn R.N., Jones T. Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur. J. Nucl. Med. 1998, 25:173-176.
24. Iancu R., Mohapel P., Brundin P., Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav. Brain Res. 2005, 162:1-10.
25. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.-C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
26. Irifune M., Sato T., Nishikawa T., Masuyama T., Nomoto M., Fukuda T., Kawahara M. Hyperlocomotion during recovery from isoflurane anesthesia is associated with increased dopamine turnover in the nucleus accumbens and striatum in mice. Anesthesiology 1997, 86:464-475.
27. Iwata S., Nomoto M., Morioka H., Miyata A. Gene expression profiling in the midbrain of striatal 6-hydroxydopamine-injected mice. Synapse 2004, 51:279-286.
28. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4029-4034.
29. Kawasaki T. Proceedings of the 2010 World Molecular Imaging Congress, Kyoto, Japan, September 8-11, 2010. Mol. Imaging Biol. 2010, 12:500-1636.
30. Kessler R.M., Ellis J.R., Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J. Comput. Assist. Tomogr. 1984, 8:514-522.
31. Koller W., O'Hara R., Weiner W., Lang A., Nutt J., Agid Y., Bonnet A.M., Jankovic J. Relationship of aging to Parkinson's disease. Adv. Neurol. 1987, 45:317-321.
32. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. NeuroImage 1996, 4:153-158.
33. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47:493-503.
34. Lewitt P.A. Levodopa for the treatment of Parkinson's disease. N. Engl. J. Med. 2008, 359:2468-2476.
35. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996, 16:834-840.
36. The mouse brain in stereotaxic coordinates 2001, Academic Press. second ed. G. Paxinos, K.B.J. Franklin (Eds.).
37. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995, 67:631-647.
38. Ribeiro M.J., Thobois S., Lohmann E., du Montcel S.T., Lesage S., Pelissolo A., Dubois B., Mallet L., Pollak P., Agid Y., Broussolle E., Brice A., Remy P. A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations. J. Nucl. Med. 2009, 50:1244-1250.
39. Slifstein M., Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl. Med. Biol. 2001, 28:595-608.
40. Smith M.P., Cass W.A. Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease. Neuroscience 2007, 144:1057-1066.
41. Sossi V., de la Fuente-Fernandez R., Schulzer M., Troiano A.R., Ruth T.J., Stoessl A.J. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann. Neurol. 2007, 62:468-474.
42. Sossi V., Holden J.E., Topping G.J., Camborde M.-L., Kornelsen R.A., McCormick S.E., Greene J., Studenov A.R., Ruth T.J., Doudet D.J. In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. J. Cereb. Blood Flow Metab. 2007, 27:1407-1415.
43. Sossi V., Dinelle K., Topping G.J., Holden J.E., Doudet D., Schulzer M., Ruth T.J., Stoessl A.J., de la Fuente-Fernandez R. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J. Neurochem. 2009, 109:85-92.
44. Stachowiak M.K., Keller R.W., Stricker E.M., Zigmond M.J. Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J. Neurosci. 1987, 7:1648-1654.
45. Topping G.J., Dinelle K., Kornelsen R., McCormick S., Holden J.E., Sossi V. Positron emission tomography kinetic modeling algorithms for small animal dopaminergic system imaging. Synapse 2010, 64:200-208.
46. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 1968, 5:107-110.
47. Van Camp N., Blockx I., Verhoye M., Casteels C., Coun F., Leemans A., Sijbers J., Baekelandt V., Van Laere K., Van der Linden A. Diffusion tensor imaging in a rat model of Parkinson's disease after lesioning of the nigrostriatal tract. NMR Biomed. 2009, 22:697-706.
48. Van Camp N., Vreys R., Van Laere K., Lauwers E., Beque D., Verhoye M., Casteels C., Verbruggen A., Debyser Z., Mortelmans L., Sijbers J., Nuyts J., Baekelandt V., Van der Linden A. Morphologic and functional changes in the unilateral 6-hydroxydopamine lesion rat model for Parkinson's disease discerned with microSPECT and quantitative MRI. MAGMA 2010, 23:65-75.
49. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley S.J., Schlyer D.J., Pappas N. A new PET ligand for the dopamine transporter: studies in the human brain. J. Nucl. Med. 1995, 36:2162-2168.
50. Votaw J., Byas-Smith M., Hua J., Voll R., Martarello L., Levey A.I., Bowman F.D., Goodman M. Interaction of isoflurane with the dopamine transporter. Anesthesiology 2003, 98:404-411.
51. Votaw J.R., Byas-Smith M.G., Voll R., Halkar R., Goodman M.M. Isoflurane alters the amount of dopamine transporter expressed on the plasma membrane in humans. Anesthesiology 2004, 101:1128-1135.
52. Zhuang X., Oosting R.S., Jones S.R., Gainetdinov R.R., Miller G.W., Caron M.G., Hen R. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1982-1987.